Developing image analysis algorithms relevant to immune-oncology

Philip Macklin is a clinician and histopathology trainee in the Oxford Deanery, currently taking time out of NHS training to complete a DPhil in Clinical Medicine. He has a medical degree from the University of Edinburgh and has been working in Oxford ever since. He is currently a Clinical Research Fellow in the Ratcliffe/Pugh Hypoxia Biology group based in the Nuffield Department of Medicine.

Philip is investigating how hypoxia within solid tumours affects anti-tumour immune responses. He is looking into whether manipulating levels of tumour hypoxia, or how infiltrating immune cells respond to this hypoxia, can increase the power of these responses to better control the growth and spread of tumours. He is particularly interested in the effects of hypoxia on the spatial distribution of different immune cell subsets within the tumour microenvironment. To do this accurately, he is collaborating with local mathematicians and software engineers to develop computer algorithms to perform robust/reliable image analysis of histology sections. Such approaches generate large datasets and, in parallel, he is developing techniques to curate and visualise the results as well as more sophisticated spatial statistics to describe these distributions.

He hopes to develop these approaches into freely available and easy to use software that will assist other researchers in Oxford to perform accurate image analysis, with particular relevance to immuno-oncology projects. Whilst likely to be used exclusively in the academic setting at first, it is possible that, in the future, these techniques could be applied to patient samples within the diagnostic histopathology laboratory to better quantitate biomarkers/prognostic features in histology images, helping to ensure that each patient receives the most appropriate treatment.

Find out more about our research below

Doctor looking at skin

Higher testosterone levels in men linked to greater melanoma risk

New research from Dr Eleanor Watts at the Nuffield Department of Population Health has found this association for the first time

Novel imaging device enters first round of development funding programme

Anna Vella is designing CAPULET: a device to increase the accuracy in delivering particle beam radiotherapy in cancer treatment

Funding to improve childhood, teenage and young adult cancer detection

Dr Defne Saatci and Professor Julia Hippisley-Cox will develop risk prediction tools using the QResearch database to support the earlier detection of childhood, teenage and young adult cancer

New partnership enables access to state-of-the-art radiotherapy machine

University of Oxford, OUH and GenesisCare have partnered to provide access to a new ViewRay MRIdian machine. It is the first of its kind in the UK and will help to improve challenging cancer treatment through faster, tailored radiotherapy.

Drinking alcohol regularly increases cancer risk in Chinese populations

New research from the Nuffield Department of Population Health shows that reducing alcohol consumption in China could be an important cancer prevention strategy

New Oxford technology assesses cancer patient vulnerability to COVID-19

New research from Prof Julia Hippisley-Cox has resulted in thousands of cancer patients being given prioritised access to the COVID-19 vaccine.

The search for pancreatic cancer biomarkers

Nuffield Department of Population Health researchers are using the China Kadoorie Biobank to identify potential protein biomarkers in the blood that could be used to predict the presence or development of pancreatic cancer

Early stage ‘red flag’ symptoms for pancreatic cancer

The ADEPTS study uses the QResearch database to better understand what ‘red flag’ symptoms may be associated with pancreatic cancer, in the hopes of promoting earlier diagnosis from primary care.

Understanding breast cancer risk in Chinese populations

Researchers from the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) are utilising the China Kadoorie Biobank to better understand how breast cancer risk factors may differ between individuals from Western and Eastern populations